$EDIT
Editas Medicine, Inc.

2021 Q4 Form 10-Q Financial Statement

#000155837021015161 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $12.47M $6.197M $62.84M
YoY Change 9.2% -90.14% 1533.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.53M $16.18M $19.94M
YoY Change 4.66% -18.83% 26.76%
% of Gross Profit
Research & Development $37.55M $29.27M $33.92M
YoY Change -38.94% -13.71% 49.4%
% of Gross Profit
Depreciation & Amortization $1.511M $1.190M $1.110M
YoY Change 28.05% 7.21% 52.05%
% of Gross Profit
Operating Expenses $54.08M $45.45M $53.85M
YoY Change -30.03% -15.6% 40.11%
Operating Profit -$39.25M $8.989M
YoY Change -536.68% -125.99%
Interest Expense $1.910M $152.0K $230.0K
YoY Change 730.43% -33.91% -86.31%
% of Operating Profit 2.56%
Other Income/Expense, Net -$1.736M $171.0K -$1.170M
YoY Change -151.44% -114.62% -171.04%
Pretax Income -$41.44M -$39.08M $7.820M
YoY Change -33.7% -599.77% -123.74%
Income Tax
% Of Pretax Income
Net Earnings -$41.44M -$39.08M $7.819M
YoY Change -33.7% -599.83% -123.74%
Net Earnings / Revenue -332.31% -630.66% 12.44%
Basic Earnings Per Share -$0.57 $0.13
Diluted Earnings Per Share -$606.1K -$0.57 $0.12
COMMON SHARES
Basic Shares Outstanding 68.40M 68.22M 62.14M
Diluted Shares Outstanding 68.22M 62.70M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $499.8M $557.8M $495.3M
YoY Change 24.31% 12.63% 12.3%
Cash & Equivalents $203.5M $259.9M $279.6M
Short-Term Investments $296.3M $298.0M $215.7M
Other Short-Term Assets $7.198M $9.516M $10.50M
YoY Change -33.96% -9.37% 66.67%
Inventory
Prepaid Expenses
Receivables $267.0K $251.0K $1.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $507.3M $567.6M $506.8M
YoY Change 21.05% 11.99% 49.41%
LONG-TERM ASSETS
Property, Plant & Equipment $17.12M $15.63M $14.07M
YoY Change 22.1% 11.1% 39.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $120.1M $99.20M $46.00M
YoY Change 9.45% 115.65%
Other Assets $6.811M $6.781M $3.877M
YoY Change 44.82% 74.9% -28.1%
Total Long-Term Assets $170.2M $149.4M $90.33M
YoY Change 10.85% 65.41% 172.51%
TOTAL ASSETS
Total Short-Term Assets $507.3M $567.6M $506.8M
Total Long-Term Assets $170.2M $149.4M $90.33M
Total Assets $677.5M $717.0M $597.2M
YoY Change 18.32% 20.07% 60.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.050M $3.402M $5.158M
YoY Change -21.19% -34.04% -22.13%
Accrued Expenses $20.19M $14.58M $20.31M
YoY Change -16.03% -28.23% 149.53%
Deferred Revenue $11.33M $22.67M $19.87M
YoY Change -45.89% 14.05% -56.81%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.88M $50.91M $54.82M
YoY Change -19.45% -7.13% -17.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $76.96M $79.32M $101.2M
YoY Change 179.84% -21.62% 10119900.0%
Total Long-Term Liabilities $76.96M $79.32M $101.2M
YoY Change 179.84% -21.62% 10119900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.88M $50.91M $54.82M
Total Long-Term Liabilities $76.96M $79.32M $101.2M
Total Liabilities $123.8M $130.2M $156.0M
YoY Change -30.82% -16.53% -3.92%
SHAREHOLDERS EQUITY
Retained Earnings -$857.7M -$816.3M -$602.7M
YoY Change 28.94% 35.44% 17.83%
Common Stock $1.412B $1.403B $1.044B
YoY Change 33.34% 34.41% 44.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $553.6M $586.8M $441.2M
YoY Change
Total Liabilities & Shareholders Equity $677.5M $717.0M $597.2M
YoY Change 18.32% 20.07% 60.37%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$41.44M -$39.08M $7.819M
YoY Change -33.7% -599.83% -123.74%
Depreciation, Depletion And Amortization $1.511M $1.190M $1.110M
YoY Change 28.05% 7.21% 52.05%
Cash From Operating Activities -$34.58M -$40.79M -$54.80M
YoY Change -13.76% -25.57% 103.87%
INVESTING ACTIVITIES
Capital Expenditures -$2.845M -$2.344M -$1.800M
YoY Change 107.66% 30.22% -20.0%
Acquisitions
YoY Change
Other Investing Activities -$19.99M -$37.32M -$150.5M
YoY Change -81.4% -75.2% 25.33%
Cash From Investing Activities -$22.84M -$39.66M -$152.3M
YoY Change -79.02% -73.95% 24.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.057M 2.496M 820.0K
YoY Change -88.38% 204.39% -98.11%
NET CHANGE
Cash From Operating Activities -34.58M -40.79M -54.80M
Cash From Investing Activities -22.84M -39.66M -152.3M
Cash From Financing Activities 1.057M 2.496M 820.0K
Net Change In Cash -56.36M -77.95M -206.3M
YoY Change -59.71% -62.21% 94.89%
FREE CASH FLOW
Cash From Operating Activities -$34.58M -$40.79M -$54.80M
Capital Expenditures -$2.845M -$2.344M -$1.800M
Free Cash Flow -$31.74M -$38.44M -$53.00M
YoY Change -18.06% -27.47% 115.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
dei Entity Central Index Key
EntityCentralIndexKey
0001650664
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37687
dei Entity Registrant Name
EntityRegistrantName
EDITAS MEDICINE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4097528
dei Entity Address Address Line1
EntityAddressAddressLine1
11 Hurley Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Trading Symbol
TradingSymbol
EDIT
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27500000
CY2021Q3 us-gaap Liabilities
Liabilities
130225000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68398540
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
259884000
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
401-9000
dei Security12b Title
Security12bTitle
Common Stock
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139682000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
297957000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
262428000
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
251000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6048000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9516000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10929000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
567608000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
419087000
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
99198000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
109664000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15631000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14020000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27801000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25128000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6781000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4703000
CY2021Q3 us-gaap Assets
Assets
717019000
CY2020Q4 us-gaap Assets
Assets
572602000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3402000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6408000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14575000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24046000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22667000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20943000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
10263000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6811000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
50907000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
58208000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18430000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19324000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
60888000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
73984000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000
CY2020Q4 us-gaap Liabilities
Liabilities
179016000
CY2021Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2020Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68392659
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62689457
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68320659
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1396000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13114000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62563457
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1403114000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1058823000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-64000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-46000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-816263000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-665197000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
586794000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
393586000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
717019000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
572602000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6197000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62841000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13075000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
79313000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29265000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33916000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
104954000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96492000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16185000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19936000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59657000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51789000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
45450000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
53852000
us-gaap Operating Expenses
OperatingExpenses
164611000
us-gaap Operating Expenses
OperatingExpenses
148281000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-39253000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8989000
us-gaap Operating Income Loss
OperatingIncomeLoss
-151536000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68968000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
152000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
226000
us-gaap Investment Income Net
InvestmentIncomeNet
432000
us-gaap Investment Income Net
InvestmentIncomeNet
2377000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
171000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1170000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
470000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15491000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-39082000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
us-gaap Net Income Loss
NetIncomeLoss
-151066000
us-gaap Net Income Loss
NetIncomeLoss
-53477000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68219742
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62144118
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67371246
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57377581
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68219742
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62697173
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67371246
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57377581
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-39082000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
us-gaap Net Income Loss
NetIncomeLoss
-151066000
us-gaap Net Income Loss
NetIncomeLoss
-53477000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-231000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-18000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-155000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39075000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7588000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-151084000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53632000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
393586000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
249459000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
27500000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12002000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12204000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-27000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-56728000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
637996000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16567000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2391000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13526000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
526000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-55256000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
613361000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2496000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10012000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-39082000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
586794000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
262437000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3047000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6220000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
587000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-37724000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
234567000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6839000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203682000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5417000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
350000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-511000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23572000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
426772000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
947000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5845000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-231000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
441152000
us-gaap Profit Loss
ProfitLoss
-151066000
us-gaap Profit Loss
ProfitLoss
-53477000
us-gaap Share Based Compensation
ShareBasedCompensation
35742000
us-gaap Share Based Compensation
ShareBasedCompensation
17483000
us-gaap Depreciation
Depreciation
3542000
us-gaap Depreciation
Depreciation
2776000
us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
13109000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1332000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
285000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5797000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
637000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1414000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4181000
edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-7080000
edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2363000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2077000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-106000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2978000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-447000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9439000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11372000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-86026000
edit Increase Decrease In Right Of Use Liability
IncreaseDecreaseInRightOfUseLiability
-7196000
edit Increase Decrease In Right Of Use Liability
IncreaseDecreaseInRightOfUseLiability
-2371000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
453000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129221000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-139743000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5132000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5786000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
21000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
304570000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
300363000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
278076000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
274500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31626000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31628000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
249458000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203839000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31065000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10833000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
526000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
350000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
281049000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215022000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
120202000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43651000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143559000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239802000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263761000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
283453000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
597000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
910000
us-gaap Operating Lease Payments
OperatingLeasePayments
8918000
us-gaap Operating Lease Payments
OperatingLeasePayments
7757000
edit Non Cash Transactions Offering Cost Included In Accounts Payable And Accrued Expenses
NonCashTransactionsOfferingCostIncludedInAccountsPayableAndAccruedExpenses
158000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9753000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Editas Medicine, Inc. (the “Company”) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, a wholly-owned subsidiary of the Bristol Myers Squibb Company (“Juno Therapeutics”), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”), which was terminated in August 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In May 2021, the Company entered into a common stock sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “ATM Facility”). As of September 30, 2021, the Company has not sold any shares of its common stock under the ATM Facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In January 2021, the Company completed a public offering whereby it sold 3,500,000 shares of its common stock and received net proceeds of approximately $216.9 million. In February 2021, the underwriters in the public offering exercised their option to purchase an additional 525,000 shares, resulting in additional net proceeds to the Company of approximately $32.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities</span> <span style="font-size:10pt;">at September 30, 2021 and anticipated interest income will enable it to fund its operating expenses and capital expenditure requirements well </span><span style="font-size:10pt;">into 2023</span><span style="font-size:10pt;">. The Company had an accumulated deficit of $816.3 million at September 30, 2021, and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</span></p>
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-816300000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
657103000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
74000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
657039000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
511820000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
64000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
511774000
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q3 edit Marketable Securities Noncurrent Number Of Securities
MarketableSecuritiesNoncurrentNumberOfSecurities
29
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
99200000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9639000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5323000
CY2021Q3 edit Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2381000
CY2020Q4 edit Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
12820000
CY2021Q3 edit Accrued Intellectual Property Fees
AccruedIntellectualPropertyFees
1606000
CY2020Q4 edit Accrued Intellectual Property Fees
AccruedIntellectualPropertyFees
4240000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
640000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
533000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
271000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
359000
CY2021Q3 edit Sublicensing Expenses
SublicensingExpenses
38000
CY2020Q4 edit Sublicensing Expenses
SublicensingExpenses
771000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14575000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24046000
edit Accounts Receivable Additions
AccountsReceivableAdditions
390000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6048000
edit Accounts Receivable Deductions
AccountsReceivableDeductions
6187000
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
251000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
94927000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29674000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25115000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14043000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11095000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15631000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14020000
edit Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11372000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
83555000
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5666000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
11372000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10012000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5846000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35742000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17483000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-39082000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
us-gaap Net Income Loss
NetIncomeLoss
-151066000
us-gaap Net Income Loss
NetIncomeLoss
-53477000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68219742
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62144118
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67371246
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57377581
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68219742
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62697173
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67371246
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57377581
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3833871
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3997614
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3833871
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4550669

Files In Submission

Name View Source Status
0001558370-21-015161-index-headers.html Edgar Link pending
0001558370-21-015161-index.html Edgar Link pending
0001558370-21-015161.txt Edgar Link pending
0001558370-21-015161-xbrl.zip Edgar Link pending
edit-20210930.xsd Edgar Link pending
edit-20210930x10q.htm Edgar Link pending
edit-20210930x10q_htm.xml Edgar Link completed
edit-20210930xex10d1.htm Edgar Link pending
edit-20210930xex10d1001.jpg Edgar Link pending
edit-20210930xex10d2.htm Edgar Link pending
edit-20210930xex10d3.htm Edgar Link pending
edit-20210930xex10d4.htm Edgar Link pending
edit-20210930xex10d5.htm Edgar Link pending
edit-20210930xex10d5001.jpg Edgar Link pending
edit-20210930xex10d5002.jpg Edgar Link pending
edit-20210930xex10d6.htm Edgar Link pending
edit-20210930xex10d7.htm Edgar Link pending
edit-20210930xex31d1.htm Edgar Link pending
edit-20210930xex31d2.htm Edgar Link pending
edit-20210930xex32d1.htm Edgar Link pending
edit-20210930_cal.xml Edgar Link unprocessable
edit-20210930_def.xml Edgar Link unprocessable
edit-20210930_lab.xml Edgar Link unprocessable
edit-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending